We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eisai and Biogen have announced that a Phase III trial has been initiated for the anti-amyloid beta protofibril antibody BAN2401, for use in patients with early Alzheimer's disease.
At last some good news for Alzheimer’s research, as Eisai and Biogen’s experimental anti beta-amyloid therapy BAN2401 hit targets in a Phase II trial in patients with the disease.
Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in patients with prodromal or mild Alzheimer’s disease (collectively known as early Alzheimer’s disease) and with positive biomarkers for brain amyloid pathology